Sorry, you need to enable JavaScript to visit this website.
 

This site is intended only for healthcare professionals resident in the United Kingdom

Prescribing information can be found at the bottom of the page

ZYVOX should only be initiated in a hospital environment and after consultation with a relevant specialist such as a microbiologist or infectious diseases specialist1.

ZYVOX (linezolid) for the Treatment of Nosocomial Pneumonia and Community Acquired Pneumonia

ZYVOX is indicated in adults for the treatment of community acquired pneumonia and nosocomial pneumonia when known or suspected to be caused by susceptible Gram positive bacteria. In determining whether ZYVOX is an appropriate treatment, the results of microbiological tests or information on the prevalence of resistance to antibacterial agents among Gram positive bacteria should be taken into consideration1.

ZYVOX is not active against infections caused by Gram negative pathogens. Specific therapy against Gram negative organisms must be initiated concomitantly if a Gram negative pathogen is documented or suspected1.

ZYVOX (linezolid) for the Treatment of Complicated Skin and Soft Tissue Infections

ZYVOX is indicated in adults for the treatment of complicated skin and soft tissue infections only when microbiological testing has established that the infection is known to be caused by susceptible Gram positive bacteria1.

ZYVOX is not active against infections caused by Gram negative pathogens. ZYVOX should only be used in patients with complicated skin and soft tissue infections with known or possible co-infection with Gram negative organisms if there are no alternative treatment options available. In these circumstances treatment against Gram negative organisms must be initiated concomitantly1.

 

Consideration should be given to official guidance on the appropriate use of antibacterial agents. 

References

  1. ZYVOX® Summary of Product Characteristics